Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NPs/PAs, pharmacists, and other HCPs involved in the diagnosis and treatment of acute lymphoblastic leukemia
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the efficacy and safety of new and emerging therapies for ALL, including immunotherapy, targeted therapies, and cellular therapies.
- Develop individualized treatment plans for patients with ALL by considering disease characteristics, treatment-related factors, and patient needs.
- Assess the role of MRD evaluation to guide prognosis and treatment planning in ALL.
- Incorporate strategies to monitor, mitigate and manage toxicities with newer therapies for ALL.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here